Added to YB: 2025-01-22
Pitch date: 2024-12-04
ADAP [bullish]
Adaptimmune Therapeutics plc
-96.25%
current return
Author Info
No bio for this author
Company Info
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom.
Market Cap
$6.8M
Pitch Price
$0.72
Price Target
2.50 (+9159%)
Dividend
N/A
EV/EBITDA
0.10
P/E
-0.09
EV/Sales
-0.85
Sector
Biotechnology
Category
special_situation
Adaptimmune Therapeutics plc - $ADAP
ADAP: FDA-approved Tecelra for sarcoma, lete-cel BLA 2025. $178M mkt cap, $30M EV. Non-natural selling pressure ending. $367M peak sales potential. Uza-cel in H&N w/ Galapagos. PRAME & CD70 in pipeline. Cash $186M, need $200M. 2x-4x peak rev = $2.04-$4.60/sh. Catalysts: ASH data, rev ramp, ATC expansion, lete-cel approval.
Read full article (11 min)